

## 2023 Results of Annual General Meeting

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act, PYC Therapeutics Limited (the 'Company') advises that the resolutions contained in the Notice of Meeting dated 24 October 2023 and considered at today's Annual General Meeting of Shareholders were all passed by the required majority following a poll conducted at the meeting. The proxies received in respect of each resolution are set in the attached proxy summary.

This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited.

For further information, please contact:

**Kevin Hart**

**Company Secretary**

[info@pyctx.com](mailto:info@pyctx.com)

### About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – **the indications with the highest likelihood of success in clinical development**<sup>1</sup>.

The Company was the first to progress a drug candidate for a blinding eye disease of childhood into human trials and is now progressing multiple 'fast-follower' programs into the clinic. For more information, visit [pyctx.com](https://pyctx.com), or follow us on LinkedIn and Twitter.

**CONTACTS:**  
**INVESTORS and MEDIA**  
[info@pyctx.com](mailto:info@pyctx.com)

<sup>1</sup> Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank <https://doi.org/10.1101/2020.11.02.20222232>

## Results of meeting

Name of entity

PYC THERAPEUTICS LIMITED

ABN/ACN/ARSN/ARBN

098 391 961

Date of meeting

24 November 2023

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolutions voted on at the meeting					If decided by poll					Proxies received			
Resolution		Result	Voting method	If s250U applies	Voted for		Voted against		Abstained	For	Against	Abstain	Discretion
No	Short description				Number	%	Number	%	Number	Number	Number	Number	Number
1	Remuneration Report	Passed	Poll	n/a	781,076,350	99.71	2,250,925	0.29	855,661	723,855,982	2,250,925	855,661	24,739,870
2	Re-Election of Dr Michael Rosenblatt	Passed	Poll	n/a	1,415,789,052	100	40,000	0.00	606,000	726,316,568	40,000	606,000	24,739,870
3	Re-Approval of Long Term Incentive Plan	Passed	Poll	n/a	779,527,108	99.58	3,271,283	0.42	755,000	722,306,740	3,271,283	755,000	24,738,870
4	Re-insertion of proportional takeover provisions	Passed	Poll	n/a	1,414,971,127	99.91	1,213,925	0.09	250,000	725,498,643	1,213,925	250,000	24,739,870